Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
Author:
Affiliation:
1. Department of Oncology; Azienda Ospedaliero Universitaria Careggi; Florence; Italy
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1442-2042.2012.03204.x/fullpdf
Reference25 articles.
1. Renal cell carcinoma;Curti;JAMA,2004
2. Renal cell carcinoma;Motzer;N. Engl. J. Med.,1996
3. Systemic therapy for renal cell carcinoma;Motzer;J. Urol.,2000
4. Immunotherapy for metastatic renal cell carcinoma;Wirth;Urol. Clin. North Am.,1993
5. Phase III randomized trial of interleukin-2 with or without linphokine-activated killer sense in the treatment of patients with advanced renal cell carcinoma;Law;Cancer,1996
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Change of Original‐ and Generic‐Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time‐Series Analysis;Journal of Clinical Pharmacy and Therapeutics;2024-01
2. 2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma – An Indian experience;Indian Journal of Cancer;2023-10
3. Efficacy of the 1<sup>st</sup> generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens;Meditsinskiy sovet = Medical Council;2022-06-18
4. Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis;Kidney Cancer;2022-03-15
5. A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2020-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3